Join Growin Stock Community!

Quince therapeutics, inc.QNCX.US Overview

US StockHealthcare
(No presentation for QNCX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

QNCX AI Insights

QNCX Overall Performance

QNCX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

QNCX Recent Performance

-15.51%

Quince therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

QNCX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

QNCX Key Information

QNCX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

QNCX Profile

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Price of QNCX

QNCX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

QNCX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.02
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
7.25
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.02
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
7.25
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is QNCX's latest earnings report released?

    The most recent financial report for Quince therapeutics, inc. (QNCX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating QNCX's short-term business performance and financial health. For the latest updates on QNCX's earnings releases, visit this page regularly.

  • How much debt does QNCX have?

    As of the end of the reporting period, Quince therapeutics, inc. (QNCX) had total debt of 17.88M, with a debt ratio of 0.16. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does QNCX have?

    At the end of the period, Quince therapeutics, inc. (QNCX) held Total Cash and Cash Equivalents of 6.45M, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is QNCX's EPS continuing to grow?

    According to the past four quarterly reports, Quince therapeutics, inc. (QNCX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.25. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of QNCX?

    Quince therapeutics, inc. (QNCX)'s Free Cash Flow (FCF) for the period is -10M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 36.9% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.